Key result
ACTA1 CFTD mutations cause muscle weakness by disrupting sarcomere function rather than structure, with mutant actin accounting for 25% and 50% of alpha-skeletal actin in patient muscle.
Authors
Loading...
May prompt reevaluation of therapeutic targets in congenital myopathies; extends mechanistic understanding of ACTA1 mutations while leaving clinical implications open.
Observational (n=3)
Clarke et al. (2007) conducted an observational in ACTA1-related congenital fiber type disproportion (n=3). ACTA1 CFTD mutations vs. ACTA1 nemaline myopathy (NM) mutations was evaluated on Basis for histological differences and muscle weakness. ACTA1 CFTD mutations cause muscle weakness by disrupting sarcomere function rather than structure, with mutant actin accounting for 25% and 50% of alpha-skeletal actin in patient muscle.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: